Consequently, treatment of head and neck cancer patients with agonistic αDR5-antibodies [30] or of tumor-bearing mice with soluble TRAIL [28,62] was able to limit tumor growth to some extent. This evidence concerns the gene TNFSF10 and neoplasm.